by Rob Hobson | Nov 29, 2011
Recently, ReSearch Pharmaceuticals Services (RPS) CEO Dan Perlman predicted that twelve of the top twenty big pharma companies in the US will be outsourcing their clinical trial work completely. Perlman expects companies to use one of two proposed models, trials done...
by Rob Hobson | Nov 25, 2011
Pearl Pathways’ co-founder and COO, Gretchen Miller Bowker, will be leading a discussion presented by ASQ Biomedical Division. The discussion will be held at the University of Indianapolis in the Schwitzer Student Center on Thursday December 1, 2011 from 5:30pm...
by Rob Hobson | Nov 11, 2011
Pearl Pathway’s recent expansion to parent Pearl IRB as well as two new divisions, Pearl ReGXP and Pearl IDEAS, was featured on Center Watch News Online on October 17th. To read the full article from Center Watch, go here.
by Rob Hobson | Nov 11, 2011
The European Medicines Agency (EMA) is drafting an outline that will clarify what products can be produced in multi-product facilities without contamination. The assessment is focusing on toxicological data that is, at times, overlooked when determining limits of...
by Rob Hobson | Nov 4, 2011
Earlier this year, Pearl Pathways’ President and CEO, Diana Caldwell, began participating in her first clinical study, Cancer Research Study – 3. Caldwell plans to be more active in clinical research and to share her experiences along the way. You can...
